Elevated Capital Advisors’s Labcorp LH Stock Holding History

Elevated Capital Advisors’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$267	Hold	1	–	–	﹤0.01%	822
2025 Q4	$251	Buy	+1	New	+$266	﹤0.01%	803

Other funds holding LH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Elevated Capital Advisors's LH Position: Q1 2026 in Review

Elevated Capital Advisors held its Labcorp (LH) position steady in Q1 2026 at 1 share worth $267. The position accounts for ﹤0.01% of the portfolio, ranked #822.

Elevated Capital Advisors first reported a position in LH in Q4 2025 and has held it in 2 quarters since. 1,031 funds tracked by Wall St. Rank hold LH as of Q1 2026.

Elevated Capital Advisors held 1 share of Labcorp worth $267 as of Q1 2026.
Elevated Capital Advisors left its Labcorp share count unchanged in Q1 2026.
Labcorp made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q1 2026, its #822 holding.
Elevated Capital Advisors first reported a position in Labcorp in Q4 2025 and has held it in 2 quarters since.
1,031 funds tracked by Wall St. Rank held Labcorp as of Q1 2026.

Based on Elevated Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.